We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Health

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What Is Romiplostim?

By Maggie J. Hall
Updated: May 17, 2024
Views: 7,862
Share

Physicians may prescribe romiplostim to patients suffering from chronic idiopathic thrombocytopenia purpura (ITP), a disease characterized by the abnormal destruction of platelets. The action of romiplostim aids in the production of platelets and is usually only prescribed when other treatment methods prove unsuccessful, as the medication may contribute to other disease processes. Individuals taking the drug can also develop serious adverse reactions.

Romiplostim belongs to a class of medications known as thrombopoietic (TPO) mimetics. The thrombopoietic analog attaches to TPO receptor sites, stimulating an intracellular response that leads to the production of megakaryocytes. Megakaryocytes are the precursor cells to platelets.

Patients diagnosed with ITP initially undergo treatment with corticosteroids or immunoglobulins. The spleen may also be removed, as it is the location of platelet destruction. Complete blood counts are monitored before and during the course of treatment. If treatment does not restore patient’s platelet levels, subcutaneous injections of romiplostim may be prescribed.

Those who receive romiplostim injections have an increased risk of developing reticulin fibrous deposits in the bone marrow, and patients previously diagnosed with the condition may experience an exacerbation of the disease. The intracellular processes that occur following TPO receptor site stimulation can also increase the risk of malignancies. Patients must be fully informed of the risks involved in receiving romiplostim. Usually, they must sign a consent form saying that they have been fully informed and agree to the initiation of treatment.

Adverse reactions or side effects commonly associated with romiplostim injections include dizziness, gastrointestinal symptoms, and insomnia. Patients may also experience bone and muscle pain, commonly associated with arthritis, or unusual numbness and tingling of the extremities. Abnormal bleeding or bruising occurring after injections may indicate that the treatment is ineffective. The symptoms may also be indicative of a more serious underlying condition. Discontinuing the medication usually produces an increase in thrombocytopenia symptoms, along with increased abnormal bleeding.

ITP occurs when antibodies attack and destroy platelets. The average person generally has a platelet count of between 150,000 and 450,000 per microliter (mcL). People suffering from ITP may have platelet levels at or below 20,000 per mcL. Without proper platelet formation or normal platelet levels, blood loses its normal clotting ability, and patients experience abnormal bleeding.

Share
WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.

Editors' Picks

Discussion Comments
Share
https://www.wisegeek.net/what-is-romiplostim.htm
Copy this link
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.